Trial Profile
A Two-Week, Randomized, Modified-Blind, Double-Dummy, Parallel-Group Efficacy and Safety Study of Arformoterol Tartrate Inhalation Solution Twice-Daily, Tiotropium Once-Daily, and Arformoterol Tartrate Inhalation Solution Twice-Daily and Tiotropium Once Daily in Subjects With Chronic Obstructive Pulmonary Disease.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Arformoterol (Primary) ; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Sumitomo Pharma America
- 01 Apr 2009 Results reported in Respiratory Medicine.
- 30 Oct 2008 Results presented at ACCP
- 30 Oct 2008 Primary endpoint 'Forced expiratory volume in 1 second' has been met.